92 related articles for article (PubMed ID: 24075095)
1. The role of sevelamer carbonate in increasing serum bicarbonate in hyperphosphatemic predialysis patients who have metabolic acidosis.
Bezzaoucha S; Pichette V; Lafrance JP; Bell R; Laurin LP; Vallée M
Int J Clin Pharmacol Ther; 2013 Dec; 51(12):989-90. PubMed ID: 24075095
[No Abstract] [Full Text] [Related]
2. Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.
Pai AB; Shepler BM
Pharmacotherapy; 2009 May; 29(5):554-61. PubMed ID: 19397463
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis.
Ketteler M; Rix M; Fan S; Pritchard N; Oestergaard O; Chasan-Taber S; Heaton J; Duggal A; Kalra PA
Clin J Am Soc Nephrol; 2008 Jul; 3(4):1125-30. PubMed ID: 18450923
[TBL] [Abstract][Full Text] [Related]
4. Sevelamer carbonate.
Barna MM; Kapoian T; O'Mara NB
Ann Pharmacother; 2010 Jan; 44(1):127-34. PubMed ID: 19955298
[TBL] [Abstract][Full Text] [Related]
5. Sevelamer worsens metabolic acidosis in hemodialysis patients.
De Santo NG; Frangiosa A; Anastasio P; Marino A; Correale G; Perna A; Di Stazio E; Stellato D; Santoro D; Di Meglio E; Iacono G; Ciacci C; Savica V; Cirillo M
J Nephrol; 2006; 19 Suppl 9():S108-14. PubMed ID: 16736432
[TBL] [Abstract][Full Text] [Related]
6. The effect of lanthanum carbonate on metabolic acidosis in patients with chronic kidney disease stage IV, V and V-D.
Beaubien-Souligny W; Bezzaoucha S; Pichette V; Lafrance JP; Bell R; Lamarche C; Ouimet D; Vallee M
Int Urol Nephrol; 2015 Jul; 47(7):1165-71. PubMed ID: 25982583
[TBL] [Abstract][Full Text] [Related]
7. Sevelamer hydrochloride dose-dependent increase in prevalence of severe acidosis in hemodialysis patients: analysis of nationwide statistical survey in Japan.
Oka Y; Miyazaki M; Matsuda H; Takatsu S; Katsube R; Mori T; Takehara K; Umeda Y; Uno F
Ther Apher Dial; 2014 Feb; 18(1):37-43. PubMed ID: 24499082
[TBL] [Abstract][Full Text] [Related]
8. Sevelamer 'carbonate': what's in a name?
Harland C; Wrong O
Nephrol Dial Transplant; 2010 Apr; 25(4):1354-5. PubMed ID: 20118068
[No Abstract] [Full Text] [Related]
9. Reduction of hyperphosphatemia is related with the reduction of C-reactive protein in dialysis patients. Study in sevelamer-resistant dialysis patients treated with chitosan chewing gum as salivary phosphate binder.
Calò LA; Savica V; Piccoli A; Fusaro M; D'Angelo A; Davis PA
Ren Fail; 2011; 33(1):11-4. PubMed ID: 21219199
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of hyperphosphatemia with sevelamer in patients with chronic renal failure].
Suñer M; Guerrero A; Montes R; Rivera M; Ruiz A; Martínez-García M; Pérez-Valdivia MA; Mateos J
Nefrologia; 2004; 24(2):142-8. PubMed ID: 15219089
[TBL] [Abstract][Full Text] [Related]
11. Sevelamer carbonate for the treatment of hyperphosphatemia in patients with kidney failure (CKD III - V).
Biggar P; Ketteler M
Expert Opin Pharmacother; 2010 Nov; 11(16):2739-50. PubMed ID: 20977406
[TBL] [Abstract][Full Text] [Related]
12. Sevelamer hydrochloride exacerbates metabolic acidosis in hemodialysis patients, depending on the dosage.
Oka Y; Miyazaki M; Takatsu S; Kunitomo K; Uno F; Maruyama M; Matsuda H
Ther Apher Dial; 2007 Apr; 11(2):107-13. PubMed ID: 17381531
[TBL] [Abstract][Full Text] [Related]
13. Long-term management of sevelamer hydrochloride-induced metabolic acidosis aggravation and hyperkalemia in hemodialysis patients.
Sonikian M; Metaxaki P; Iliopoulos A; Marioli S; Vlassopoulos D
Ren Fail; 2006; 28(5):411-8. PubMed ID: 16825091
[TBL] [Abstract][Full Text] [Related]
14. A review article: sevelamer hydrochloride and metabolic acidosis in dialysis patients.
Oka Y; Miyazaki M; Takatsu S; Oohara T; Toda K; Uno F; Matsuda H
Cardiovasc Hematol Disord Drug Targets; 2008 Dec; 8(4):283-6. PubMed ID: 19075639
[TBL] [Abstract][Full Text] [Related]
15. Assessment of phosphate binding by sevelamer carbonate powder for oral suspension mixed in foods.
Hanus M; Zhorov E; Brommage D; Plone M; Holmes-Farley SR
Nephrol Nurs J; 2012; 39(3):239-43, 255. PubMed ID: 22866363
[TBL] [Abstract][Full Text] [Related]
16. Peritoneal dialysis patients using sevelamer do not present the acidosis problems that hemodialysis patients do.
Pagé D; Knoll G
Adv Perit Dial; 2005; 21():185-7. PubMed ID: 16686315
[TBL] [Abstract][Full Text] [Related]
17. Hyperphosphatemic familial tumoral calcinosis: response to acetazolamide and postulated mechanisms.
Finer G; Price HE; Shore RM; White KE; Langman CB
Am J Med Genet A; 2014 Jun; 164A(6):1545-9. PubMed ID: 24668887
[TBL] [Abstract][Full Text] [Related]
18. Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients.
Ahmadi F; Shamekhi F; Lessan-Pezeshki M; Khatami MR
Saudi J Kidney Dis Transpl; 2012 Sep; 23(5):934-8. PubMed ID: 22982903
[TBL] [Abstract][Full Text] [Related]
19. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
Itoh K; Tanaka M; Hashiguchi J; Funakoshi S; Nakano H; Kubo H; Kono T; Uchino J; Masaki K; Date T; Shigematsu T;
Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160
[TBL] [Abstract][Full Text] [Related]
20. Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS).
Bommer J; Locatelli F; Satayathum S; Keen ML; Goodkin DA; Saito A; Akiba T; Port FK; Young EW
Am J Kidney Dis; 2004 Oct; 44(4):661-71. PubMed ID: 15384017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
